Summit shares plummet on DMD drug failure
Shares in Oxford University spin out Summit Therapeutics have taken a nosedive after the firm’s flagship drug ezutromid failed to hit targets in a mid-stage trial in patients with Duchenne muscular dystrophy (DMD).
Read More
